Validating radiographic progression-free survival

Radiographic progression in rheumatoid arthritis.

Radiographic progression is an important outcome measure in clinical trials and observational studies with patients with rheuamtoid arthritis. In this article we describe several aspects of measuring radiographic progression. We introduce the scoring method, discuss scoring methodology and issues regarding reliability of scoring, describe the relation between disease activity, radiographic prog...

Monitoring Radiographic Brain Tumor Progression

Determining radiographic progression in primary malignant brain tumors has posed a significant challenge to the neuroncology community. Glioblastoma multiforme (GBM, WHO Grade IV) through its inherent heterogeneous enhancement, growth patterns, and irregular nature has been difficult to assess for progression. Our ability to detect tumor progression radiographically remains inadequate. Despite ...

Fig 1. Biochemical progression-free survival stratified by preoperative PSA

Progression-free survival remains debatable endpoint in cancer trials.

I n recent years the U.S. Food and Drug Administration has approved cancer therapies on the basis of improved progression-free survival (PFS), including several drugs for the treatment of metastatic kidney cancer. Clinicians who treat kidney cancer patients are convinced that the agency made the right move, and some even contend that overall survival (OS) is no longer a useful endpoint in this ...

Chromothripsis and progression-free survival in metastatic colorectal cancer

Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromot...